| Description | Sabatolimab (MBG453), a humanized IgG4 (S228P) antibody targeting TIM-3, is a potent inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab has potential immunosuppressive activity and selectively binds to TIM-3 on immune cells and bone marrow cells. |
| Synonyms | MBG453, NVP-MBG453 |
| molecular weight | N/A |
| CAS | 2252262-24-9 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1): 1–2. |